Credits: Canva
Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.
The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.
The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.
The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.
The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.
The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.
Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."
The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.
However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.
Credit: PA News Agency
Sunlight brings energy, positivity and vitamin D, but not for two-year-old Mollie Murray from Scotland, who has a rare genetic disorder that makes her “allergic” to the sun.
She is reportedly the only child in the UK known to be living with xeroderma pigmentosum (XP), a condition that makes the skin extremely sensitive to ultraviolet (UV) light.
The incurable disorder puts Mollie at risk of severe sun damage year-round. She can only safely go outside in protective full-length clothing or after dark.
“She burns all year round and has burnt in November before,” her mother, Kirsty Campbell, 35, a charge nurse, was quoted as saying to The Sun.
“Everyday life is difficult as she needs full protective outerwear for going outside and sun cream every two hours under her clothes.”
Now, thanks to the charity The Archie Foundation, UV-resistant film installed at Mollie’s home last month means she can play indoors during the day without the curtains being closed.
“It means she can do simple things like look outside for the postman or draw in daylight. My ex-partner was having to take playpark equipment into his house as it wasn’t safe outside. She’s so happy running around like a normal child,” her father, Ryan Murray, 34, said.
Mollie was in and out of hospital from infancy with symptoms including seizures and severe reflux.
She first experienced severe sunburn on an overcast day in May 2025. It happened again two months later, eventually leading to her diagnosis with XPF.
Doctors have advised that Mollie is 10,000 times more likely to develop skin cancer than other children. Campbell also uses a UV monitor to check readings in every room and ensure it is safe for Mollie.
The Sun said that her family has been told she may develop neurological impairment and mobility problems in her 40s and 50s, but that she should have a relatively normal childhood.
The National Institutes of Health (NIH) describes XP as a rare autosomal recessive genetic disorder marked by extreme sensitivity to UV radiation, changes in skin pigmentation, skin cancer and, in some cases, neurological problems.
The condition usually appears in early childhood and significantly increases the risk of skin cancer.
XP affects roughly one in a million people in the US and Europe, although it is more common in some other parts of the world.
XP itself is not cancer, but it can increase the risk of skin cancer by thousands of times. Other cancers may also be more common in people with the condition.
XP is caused by mutations in specific genes that affect the body’s ability to repair UV-induced DNA damage. It is inherited from parents.
XP can be diagnosed through specialised laboratory tests, including studies of cellular sensitivity to UV radiation, chromosomal breakage, complementation studies and gene sequencing.
But there is currently no cure for XP. Management focuses on avoiding UV exposure, monitoring for complications and treating symptoms.
For Mollie’s family, the priority is to protect her while allowing her to experience as much normality as possible. The UV-resistant film has made a small but significant difference, allowing her to look outside, draw in daylight and play indoors without keeping the curtains closed.
Mollie’s family hopes to give her the highest possible quality of life while keeping her safe.
Credit: AI
An 8-year-old Louisiana girl has died after contracting Naegleria fowleri, the rare “brain-eating amoeba” infection believed to have been acquired while swimming in Lake Claiborne.
The girl, identified by her family as Lillian Smart of Ruston, died on August 22, just one day after her eighth birthday. She had been hospitalised since August 15 after developing the infection.
The Louisiana Department of Health confirmed the case on August 19 but has not publicly identified the child. The tragedy has renewed attention on an extremely rare and fatal infection.
The amoeba then can travel along the olfactory nerves through the nasal cavity and reach the brain, where it causes primary amebic meningoencephalitis (PAM). Also, swallowing contaminated water does not cause PAM, and the infection does not spread from person to person. PAM causes severe inflammation and destruction of brain tissue.
The illness can initially resemble other infections, with symptoms including headache, fever, nausea and vomiting. As the disease progresses, patients may develop advanced symptoms like stiff neck, confusion, hallucinations, seizures, and eventually coma.
One of the biggest challenges is the speed at which the infection progresses. According to recent CDC data cited in coverage of the Louisiana case, 173 Naegleria fowleri infections were documented in the US between 1937 and 2025, with only four known survivors. That puts the fatality rate at roughly 97%.
The initial symptoms of PAM can look like bacterial or viral meningitis, which can make the infection difficult to recognise immediately. An individual may initially experience fever, headache, nausea and vomiting before developing neurological symptoms.
By the time the amoeba is identified, significant brain inflammation may already have occurred. Diagnosis can involve testing cerebrospinal fluid or brain tissue for the organism. So, rare early symptoms and rapid progression makes early diagnosis of this infection particularly difficult.
There is no single drug that reliably cures PAM. Because so few cases occur, there have been no large clinical trials establishing a standard treatment regimen.
Doctors have used combinations of antimicrobial and antifungal medicines in survivors and severe cases, with treatment often including drugs such as amphotericin B and miltefosine, alongside intensive supportive care.
The CDC notes that successful treatment has involved combinations of several medicines, but outcomes remain poor.
The CDC recommends avoiding activities in warm freshwater, particularly when water temperatures are high. For people who do enter such water, precautions include:
Credit: X
Actor Michael Wright, best known for playing Eddie King Jr. in the 1991 musical drama The Five Heartbeats, has died at the age of 70 in Los Angeles. According to his kin, Wright died on August 19. His death was linked to heart failure along with complications from Marchiafava-Bignami disease, a rare degenerative neurological condition.
His wife, Susan Wright, announced his death in a social media post, “It is with profound sadness and an unimaginable heaviness in my heart that I share the passing of my beloved husband, Michael Wright,” Susan wrote, remembering the actor as a “loved one, a friend, and an extraordinary artist whose work touched generations.”
According to a statement from Wright’s family, he suffered heart failure together with complications from Marchiafava-Bignami disease. MBD is a rare neurological disorder that primarily affects the corpus callosum, the thick bundle of nerve fibres connecting the brain’s two hemispheres.
It is most commonly associated with severe alcohol use disorder and nutritional deficiencies, although it can occur in other circumstances.
The condition can cause symptoms including confusion, impaired consciousness, problems with movement, seizures and changes in cognitive function. As MBD is extremely rare, doctors may have difficulty recognising it, particularly in its early stages.
Wright's cause of death was heart failure due to the neurological disease. Heart failure occurs when the heart cannot pump enough blood to meet the body's needs. Depending on the type and severity, this can lead to breathlessness, fatigue, swelling in the legs, rapid heartbeat and reduced ability to perform everyday activities.
Heart failure can develop because of conditions including coronary artery disease, high blood pressure, heart attacks, cardiomyopathy and abnormal heart rhythms. In Wright's case, his family said heart failure occurred alongside complications from MBD. They did not publicly provide further details about what caused his heart failure.
Also read: How Genetic and Genomic Testing Can Help Women Make Smarter Cancer Decisions
His most memorable performance came in The Five Heartbeats, where he played Eddie King Jr., the troubled lead singer of a fictional R&B group. He also appeared in television series including V and HBO's Oz.
Wright's career continued into later years, with his final credited appearances including the television series Black Lightning and the 2025 film Dope King.
Susan Wright said the family has requested privacy while grieving and said further details about his life and legacy would be shared later. She said she was experiencing “profound sadness and an unimaginable heaviness” following his death.
She remembered her husband not only for his acting career but also as a loved one, friend and artist whose work had reached generations of audiences. Wright is survived by his wife, daughter, stepchildren and other family members.
© 2024 Bennett, Coleman & Company Limited